Ctc Alternative Strategies, Ltd. Glycomimetics Inc Transaction History
Ctc Alternative Strategies, Ltd.
- $160 Billion
- Q1 2024
A detailed history of Ctc Alternative Strategies, Ltd. transactions in Glycomimetics Inc stock. As of the latest transaction made, Ctc Alternative Strategies, Ltd. holds 17,700 shares of GLYC stock, worth $4,956. This represents 0.03% of its overall portfolio holdings.
Number of Shares
17,700Holding current value
$4,956% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding GLYC
# of Institutions
81Shares Held
36.8MCall Options Held
969KPut Options Held
636K-
Bvf Inc San Francisco, CA9.54MShares$2.67 Million0.86% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$2.4 Million1.39% of portfolio
-
Nea Management Company, LLC Timonium, MD3.84MShares$1.07 Million0.81% of portfolio
-
Octagon Capital Advisors LP New York, NY3MShares$840,0001.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$773,3540.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $14.7M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...